| Reference |
|---|
Wu Q, Ellis H, Siravegna G, Michel A, Norden B, Fece de la Cruz F, et al. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clin Cancer Res. 2024;30:198-208 pubmed publisher |
Wang M, Liu J, Liao X, Yi Y, Xue Y, Yang L, et al. The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance. Redox Biol. 2023;67:102931 pubmed publisher |
Rios Garcia M, Meissburger B, Chan J, de Guia R, Mattijssen F, Roessler S, et al. Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death. Adv Sci (Weinh). 2022;9:e2104291 pubmed publisher |
Moon H, Park H, Chae M, Choi H, Kim D, Ro S. Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways. BMC Cancer. 2022;22:423 pubmed publisher |
Prieto Garcia C, Hartmann O, Reissland M, Braun F, Bozkurt S, Pahor N, et al. USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. Mol Oncol. 2022;: pubmed publisher |
Jayashankar V, Edinger A. Macropinocytosis confers resistance to therapies targeting cancer anabolism. Nat Commun. 2020;11:1121 pubmed publisher |
Kinoh H, Shibasaki H, Liu X, Yamasoba T, Cabral H, Kataoka K. Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance. J Control Release. 2020;321:132-144 pubmed publisher |
Schaefer T, Ramadoss A, Leu S, Tintignac L, Tostado C, Bink A, et al. Regulation of glioma cell invasion by 3q26 gene products PIK3CA, SOX2 and OPA1. Brain Pathol. 2019;29:336-350 pubmed publisher |
Razavi P, Chang M, Xu G, Bandlamudi C, Ross D, VASAN N, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 2018;34:427-438.e6 pubmed publisher |
Roof A, Jirawatnotai S, Trudeau T, Kuzyk C, Wierman M, Kiyokawa H, et al. The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. Endocrinology. 2018;159:2421-2434 pubmed publisher |
Romano G, Chen P, Song P, McQuade J, Liang R, Liu M, et al. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018;8:556-567 pubmed publisher |
Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold D, et al. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models. Mol Cancer. 2017;16:93 pubmed publisher |
Welsch M, Kaplan A, Chambers J, Stokes M, Bos P, Zask A, et al. Multivalent Small-Molecule Pan-RAS Inhibitors. Cell. 2017;168:878-889.e29 pubmed publisher |
Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, et al. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. Liver Int. 2016;36:1176-86 pubmed publisher |
Stoy C, Sundaram A, Rios Garcia M, Wang X, Seibert O, Zota A, et al. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. EMBO Mol Med. 2015;7:1048-62 pubmed publisher |
Sathe A, Guerth F, Cronauer M, Heck M, Thalgott M, Gschwend J, et al. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer. 2014;111:2103-13 pubmed publisher |
Kohsaka S, Shukla N, Ameur N, Ito T, Ng C, Wang L, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46:595-600 pubmed publisher |
Zhao J, Liu Z, Wang L, Shin E, Loda M, Roberts T. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A. 2005;102:18443-8 pubmed |
